BR112020019577A2 - Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk - Google Patents

Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk Download PDF

Info

Publication number
BR112020019577A2
BR112020019577A2 BR112020019577-4A BR112020019577A BR112020019577A2 BR 112020019577 A2 BR112020019577 A2 BR 112020019577A2 BR 112020019577 A BR112020019577 A BR 112020019577A BR 112020019577 A2 BR112020019577 A2 BR 112020019577A2
Authority
BR
Brazil
Prior art keywords
cancer
trametinib
dabrafenib
compound
pharmaceutically acceptable
Prior art date
Application number
BR112020019577-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Matthew John Meyer
Youzhen Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112020019577A2 publication Critical patent/BR112020019577A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020019577-4A 2018-03-30 2019-03-29 Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk BR112020019577A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650744P 2018-03-30 2018-03-30
US62/650,744 2018-03-30
PCT/IB2019/052601 WO2019186488A1 (en) 2018-03-30 2019-03-29 A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor

Publications (1)

Publication Number Publication Date
BR112020019577A2 true BR112020019577A2 (pt) 2021-01-05

Family

ID=66397350

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020019577-4A BR112020019577A2 (pt) 2018-03-30 2019-03-29 Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk

Country Status (13)

Country Link
US (1) US20210121460A1 (https=)
EP (1) EP3773586A1 (https=)
JP (1) JP2021519285A (https=)
KR (1) KR20200138303A (https=)
CN (1) CN111936141A (https=)
AU (1) AU2019246719B2 (https=)
BR (1) BR112020019577A2 (https=)
CA (1) CA3094780A1 (https=)
CL (1) CL2020002505A1 (https=)
IL (1) IL277380A (https=)
MX (1) MX2020010231A (https=)
RU (1) RU2020135055A (https=)
WO (1) WO2019186488A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021171261A1 (en) * 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
EP4110341A2 (en) * 2020-02-28 2023-01-04 Novartis AG A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005252110B2 (en) 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2014342338B2 (en) * 2013-11-01 2016-12-01 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor

Also Published As

Publication number Publication date
WO2019186488A1 (en) 2019-10-03
CL2020002505A1 (es) 2021-03-05
KR20200138303A (ko) 2020-12-09
JP2021519285A (ja) 2021-08-10
CN111936141A (zh) 2020-11-13
IL277380A (en) 2020-11-30
RU2020135055A (ru) 2022-05-05
US20210121460A1 (en) 2021-04-29
MX2020010231A (es) 2020-10-28
AU2019246719A1 (en) 2020-10-01
CA3094780A1 (en) 2019-10-03
EP3773586A1 (en) 2021-02-17
AU2019246719B2 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
BR112021015632A2 (pt) Combinação farmacêutica que compreende tno155 e ribociclibe
US9486445B2 (en) Combination therapy for proliferative disorders
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
CN118201616A (zh) 用于癌症的wee1抑制剂
TW202207942A (zh) 包含ｃｒａｆ抑制劑的治療組合
BR112020019577A2 (pt) Combinação farmacêutica tripla compreendendo dabrafenibe, trametinibe e um inibidor de erk
US12606616B2 (en) PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
TW202114694A (zh) 四環化合物及其鹽類、組合物、及彼等之使用方法
US20140303146A1 (en) Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias
TW202241415A (zh) 通路調節劑、含其的醫藥組成物、其用途和採用其的治療方法
US20220354874A1 (en) Therapeutic compositions and methods for treating cancers
BR112018005771B1 (pt) Uso de um composto
EP4656193A1 (en) Pharmaceutical composition for treating tumors
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
WO2025188783A9 (en) Therapeutic compositions and methods for treating cancers
JP2023516155A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｒａｆ阻害剤又はｐｄ－１阻害剤を含む三重の医薬品の組合せ
CN120417928A (zh) 联合治疗肿瘤的药物

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements